Hantz Financial Services Inc. Increases Stock Position in GSK plc (NYSE:GSK)

Hantz Financial Services Inc. lifted its holdings in shares of GSK plc (NYSE:GSK) by 9.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,416 shares of the pharmaceutical company’s stock after buying an additional 7,858 shares during the period. Hantz Financial Services Inc.’s holdings in GSK were worth $2,956,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Eastern Bank purchased a new position in GSK in the third quarter worth $26,000. Sunbelt Securities Inc. lifted its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners boosted its holdings in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares in the last quarter. ST Germain D J Co. Inc. grew its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares during the period. Finally, Fortitude Family Office LLC purchased a new position in GSK in the third quarter valued at about $42,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

NYSE GSK opened at $35.35 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock has a market cap of $73.27 billion, a price-to-earnings ratio of 22.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The business has a fifty day moving average of $34.01 and a 200-day moving average of $37.73.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.